Add BrightSurf on Google Email

Princess Máxima Center for Pediatric Oncology


Breakthrough treatment for weight dysregulation after brain tumors

A clinical trial has shown that setmelanotide, a new drug, can achieve significant weight loss in people whose weight has become dysregulated following treatment for a brain tumor. The treatment resulted in a 20% reduction in BMI, with participants experiencing substantial health benefits.

SourcePrincess Máxima Center for Pediatric Oncology·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJul 8, 2026

European study offers clearer picture of childhood brain tumor survival

A European study analyzed data from over 30,000 children with brain tumors, providing a clear overview of their survival outcomes. The study found that differences in survival rates between countries are smaller than previously thought, suggesting improved access to similar treatments across Europe.

SourcePrincess Máxima Center for Pediatric Oncology·JournalThe Lancet Oncology·TypeData/statistical analysis·DateJul 28, 2025

Higher breast cancer risk after certain forms of childhood cancer treatment

A large-scale international study of childhood cancer survivors found that women who received high-dose doxorubicin chemotherapy without chest radiation have a significantly increased risk of breast cancer before age 40. The researchers are calling for broadening guidelines for breast cancer screening in these patients.

SourcePrincess Máxima Center for Pediatric Oncology·JournalNature Medicine·TypeObservational study·DateSep 11, 2023

Concentration of surgery has improved operations for childhood cancer

Researchers at the Princess Máxima Center found that concentrating surgery for children with neuroblastoma resulted in shorter operation times and reduced blood loss. The study also showed a decrease in side effects, although further research is needed to confirm improved survival rates.

SourcePrincess Máxima Center for Pediatric Oncology·JournalEuropean Journal of Surgical Oncology·TypeData/statistical analysis·DateDec 19, 2022

Extending chemo slashes risk of aggressive childhood leukemia coming back

A new treatment protocol has been shown to significantly reduce the risk of aggressive childhood leukemia returning after chemotherapy. The ALL-11 protocol, which includes an extra year of maintenance chemotherapy for children with specific genetic mutations, has improved five-year survival rates and quality of life for these patients....

SourcePrincess Máxima Center for Pediatric Oncology·TypeRandomized controlled/clinical trial·DateDec 10, 2022

One third of children with a kidney tumor has hereditary predisposition

A new study by the Princess Máxima Center for Pediatric Oncology has found that one third of children with a Wilms' tumor, the most common form of childhood kidney cancer, have a hereditary predisposition. This discovery has led to the implementation of extensive genetic testing for all children with this disease in the Netherlands.

SourcePrincess Máxima Center for Pediatric Oncology·JournalJournal of Clinical Oncology·TypeObservational study·DateMar 1, 2022

Protein activity reveals new childhood ALL combination treatment strategy

Scientists at the Princess Máxima Center for Pediatric Oncology discovered a new combination treatment strategy for childhood T-cell acute lymphoblastic leukemia (T-ALL) by analyzing protein activity. The study found that blocking specific proteins, such as LCK and SRC, in combination with an overactive chain reaction of INSR/IGF-1R, k...

SourcePrincess Máxima Center for Pediatric Oncology·JournalNature Communications·TypeExperimental study·DateFeb 25, 2022

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

A new study published in Blood Cancer Discovery reveals that children with acute myeloid leukemia (AML) who have more DNA changes in their blood stem cells are more likely to survive. The researchers hope that this finding can be used as a tool to identify high-risk patients and improve treatment outcomes.

SourcePrincess Máxima Center for Pediatric Oncology·JournalBlood Cancer Discovery·TypeExperimental study·DateAug 6, 2021